Home › Funds › ADAR1 Capital Management, LLC › OVID
ADAR1 Capital Management, LLC position in OVID
OVID THERAPEUTICS INC · Health Care
ADAR1 Capital Management, LLC reported holding 7,417,479 shares of OVID (OVID THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$20.0M, representing 1.11% of its reported portfolio and ranking #21 among its reported holdings. ADAR1 Capital Management, LLC has disclosed OVID holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's OVID position evolved
ADAR1 Capital Management, LLC first disclosed a stake in OVID in Q4 2023 at 13,246 shares (US$43K). The position peaked in Q2 2026 at 7,417,479 shares, worth US$20.0M. Across 11 filings, ADAR1 Capital Management, LLC increased the stake 7 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 7,417,479 shares valued at US$20.0M — an increase of 2,873,366 shares quarter over quarter.. Notable position changes include a 97% increase in Q3 2024 (shares fell 21% over the following quarter), a 246% increase in Q4 2024 (shares fell 67% over the following quarter), a 33257% increase in Q4 2025 (shares rose 36% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 13.25K | $42.65K | New |
| Q1 2024 | 16.45K | $50.16K | Add |
| Q2 2024 | 19.19K | $14.76K | Add |
| Q3 2024 | 37.74K | $44.54K | Add |
| Q4 2024 | 130.53K | $121.88K | Add |
| Q1 2025 | 115.87K | $36.14K | Reduce |
| Q2 2025 | 115.87K | $38.23K | Hold |
| Q3 2025 | 12.85K | $16.70K | Reduce |
| Q4 2025 | 4.29M | $6.98M | Add |
| Q1 2026 | 4.54M | $10.09M | Add |
| Q2 2026 | 7.42M | $19.95M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OVID and 13F data
OVID (OVID THERAPEUTICS INC) is a Health Care company. 52 other funds we track also report a position in OVID — the largest reported positions include Affinity Asset Advisors, LLC (US$27.3M), SILVERARC CAPITAL MANAGEMENT, LLC (US$8.3M), STEMPOINT CAPITAL LP (US$6.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OVID
- Affinity Asset Advisors, LLC 10.14M sh · $27.29M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.10M sh · $8.34M · Q2 2026
- STEMPOINT CAPITAL LP 2.42M sh · $6.50M · Q2 2026
- Ikarian Capital, LLC 2.27M sh · $6.11M · Q2 2026
- Propel Bio Management, LLC 1.12M sh · $3.00M · Q2 2026
- Rosalind Advisors, Inc. 1.11M sh · $2.98M · Q2 2026
- Sio Capital Management, LLC 1.01M sh · $2.70M · Q2 2026
- Saturn V Capital Management LP 663.06K sh · $1.78M · Q2 2026
- Ally Bridge Group (NY) LLC 624.56K sh · $1.68M · Q2 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held OVID?
ADAR1 Capital Management, LLC has disclosed OVID holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is ADAR1 Capital Management, LLC's current position in OVID?
As of Q2 2026, ADAR1 Capital Management, LLC holds 7.42M shares of OVID (OVID THERAPEUTICS INC), valued at $19.95M, representing 1.11% of its reported portfolio and ranking #21.
Has ADAR1 Capital Management, LLC been buying or selling OVID?
In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC increased its position in OVID. The position peaked in Q2 2026 at 7.42M shares.
Which other funds hold OVID?
Other major institutional holders of OVID include Affinity Asset Advisors, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, STEMPOINT CAPITAL LP, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.